Stockscreener 앱 받기
3.20
0.31%
0.01
전일 마감가:
$3.19
열려 있는:
$3.14
하루 거래량:
2,487
Relative Volume:
0.14
시가총액:
$16.10M
수익:
-
순이익/손실:
$-16.35M
주가수익비율:
-1.0492
EPS:
-3.05
순현금흐름:
$-11.88M
1주 성능:
+6.31%
1개월 성능:
-2.44%
6개월 성능:
-42.34%
1년 성능:
-33.30%
1일 변동 폭
$3.05
$3.2899
1주일 범위
$3.01
$3.3616
52주 변동 폭
$2.75
$11.79
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.2899 | 16.10M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.32 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.25 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.17 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.46 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.00 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) - Aktiellt
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
Lipocine Inc. Reports 2024 Financial Turnaround - TipRanks
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Lipocine announces FDA labeling changes for testosterone products - TipRanks
FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - The AM Reporter
LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa
LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):